Dogwood Therapeutics IncNASDAQ:DWTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.8100/ 1
- Ask / Lots4.3700/ 2
- Open / Previous Close--- / 4.0100
- Day Range---
- 52 Week Range
- Volume147
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DWTX |
|---|---|---|
| 09:32 ET | 6976 | 4 |
| 09:34 ET | 253 | 4.0783 |
| 09:36 ET | 163 | 3.904 |
| 09:38 ET | 666 | 4.1331 |
| 09:39 ET | 100 | 4.035 |
| 09:43 ET | 970 | 3.85 |
| 09:45 ET | 1200 | 3.9 |
| 09:48 ET | 9877 | 4.05 |
| 09:50 ET | 1587 | 4.01 |
| 09:52 ET | 100 | 4 |
| 09:54 ET | 1246 | 4.0061 |
| 09:57 ET | 100 | 4.0001 |
| 10:01 ET | 500 | 3.97 |
| 10:03 ET | 100 | 3.88 |
| 10:10 ET | 2027 | 3.9599 |
| 10:17 ET | 400 | 3.91 |
| 10:19 ET | 1611 | 3.91 |
| 10:21 ET | 3600 | 3.905 |
| 10:24 ET | 950 | 4 |
| 10:28 ET | 100 | 3.91 |
| 10:30 ET | 2400 | 3.91 |
| 10:32 ET | 800 | 3.905 |
| 10:44 ET | 100 | 3.9365 |
| 10:46 ET | 1200 | 3.91 |
| 10:48 ET | 9694 | 3.9 |
| 10:50 ET | 29906 | 3.875 |
| 10:51 ET | 2156 | 3.8999 |
| 10:55 ET | 465 | 3.852555 |
| 10:57 ET | 5400 | 3.86 |
| 11:00 ET | 2996 | 3.8501 |
| 11:08 ET | 250 | 3.8666 |
| 11:11 ET | 200 | 3.8501 |
| 11:13 ET | 100 | 3.85 |
| 11:15 ET | 476 | 3.875 |
| 11:20 ET | 206 | 3.8501 |
| 11:27 ET | 2250 | 4.0236 |
| 11:31 ET | 1400 | 3.93 |
| 11:33 ET | 400 | 3.98 |
| 11:38 ET | 200 | 3.945 |
| 11:40 ET | 3600 | 3.9 |
| 11:47 ET | 420 | 4.0109 |
| 11:51 ET | 779 | 4.02 |
| 11:58 ET | 100 | 3.9 |
| 12:32 ET | 100 | 3.9585 |
| 12:41 ET | 200 | 3.91 |
| 01:42 ET | 10166 | 3.8942 |
| 01:46 ET | 1195 | 3.9 |
| 01:51 ET | 902 | 3.8699 |
| 01:53 ET | 860 | 3.8594 |
| 01:57 ET | 213 | 3.8505 |
| 02:18 ET | 331 | 3.8986 |
| 02:44 ET | 361 | 3.9 |
| 02:54 ET | 100 | 3.9 |
| 03:02 ET | 100 | 3.875 |
| 03:21 ET | 2878 | 3.935 |
| 03:23 ET | 100 | 3.8814 |
| 03:43 ET | 621 | 3.89 |
| 03:45 ET | 1000 | 3.945 |
| 03:59 ET | 2039 | 4.01 |
Oct 9, 2024
DJ Virios Therapeutics Is Maintained at Neutral by HC Wainwright & Co., from 2:32PM ET on Wednesday Oct 09, 2024 by Dow Jones
2:32PM ET on Wednesday Oct 09, 2024 by Dow Jones
Oct 7, 2024
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Virios Therapeutics, Inc. Merger, from 5:25PM ET on Monday Oct 07, 2024 by Dow Jones
5:25PM ET on Monday Oct 07, 2024 by Dow JonesSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders, from 12:18PM ET on Monday Oct 07, 2024 by Dow Jones
12:18PM ET on Monday Oct 07, 2024 by Dow JonesVIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders, from 8:44AM ET on Monday Oct 07, 2024 by Dow Jones
8:44AM ET on Monday Oct 07, 2024 by Dow JonesVirios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX"), from 7:05AM ET on Monday Oct 07, 2024 by Dow Jones
7:05AM ET on Monday Oct 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dogwood Therapeutics Inc | 4.5M | -0.6x | --- |
Chromocell Therapeutics Corp | 4.4M | -0.5x | --- |
180 Life Sciences Corp | 4.4M | -0.2x | --- |
Hepion Pharmaceuticals Inc | 4.3M | -0.1x | --- |
Qualigen Therapeutics Inc | 4.3M | -0.1x | --- |
Lixte Biotechnology Holdings Inc | 4.3M | -1.0x | --- |
Company Information
Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.
Contact Information
- Headquarters
- 44 Milton AvenueALPHARETTA, GA, United States 30009
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Gregory Duncan
- Chief Financial Officer
- Angela Walsh
- Senior Vice President of Operations
- Ralph Grosswald
- Chief Medical Officer
- R. Michael Gendreau
- Director
- Melvin Toh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.58 |
EPS | $-6.51 |
Book Value | $4.94 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
